Evaluation of continuous positive airway pressure therapy on renin-angiotensin system activity in obstructive sleep apnea

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 5, 2014, Pages 572-580

  Nicholl, David D M ^a,b   Hanly, Patrick J ^a,c,d   Poulin, Marc J ^b,d   Handley, George B ^e   Hemmelgarn, Brenda R ^a,b,f   Sola, Darlene Y ^a,b   Ahmed, Sofia B ^a,b,f  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c FOOTHILLS HOSPITAL   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e Healthy Heart Sleep Company   (Canada)

^f Alberta Kidney Disease Network   (Canada)

Author keywords

Continuous positive airway pressure; Nocturnal hypoxemia; Obstructive sleep apnea; Renal hemodynamics; Renin Angiotensin system

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SODIUM;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD OXYGEN TENSION; CLINICAL ARTICLE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPOXEMIA; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; PLASMA RENIN ACTIVITY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESPIRATORY DISTURBANCE INDEX; SLEEP DISORDERED BREATHING; SODIUM URINE LEVEL; ADOLESCENT; CLINICAL TRIAL; KIDNEY; KIDNEY FUNCTION TEST; MIDDLE AGED; NOCTURNAL HYPOXEMIA; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

CONTINUOUS POSITIVE AIRWAY PRESSURE; NOCTURNAL HYPOXEMIA; OBSTRUCTIVE SLEEP APNEA; RENAL HEMODYNAMICS; RENIN-ANGIOTENSIN SYSTEM;

ADOLESCENT; ADULT; AGED; CONTINUOUS POSITIVE AIRWAY PRESSURE; FEMALE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; SLEEP APNEA, OBSTRUCTIVE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908145839     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201403-0526OC     Document Type: Article

References (67)

1. Markou N, Kanakaki M, Myrianthefs P, Hadjiyanakos D, Vlassopoulos D, Damianos A, Siamopoulos K, Vasiliou M, Konstantopoulos S. Sleep-disordered breathing in nondialyzed patients with chronic renal failure. Lung 2006;184:43-49.
2. Hanly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001;344:102-107.
3. Nicholl DD, Ahmed SB, Loewen AH, Hemmelgarn BR, Sola DY, Beecroft JM, Turin TC, Hanly PJ. Declining kidney function increases the prevalence of sleep apnea and nocturnal hypoxia. Chest 2012;141:1422-1430.
4. Roumelioti ME, Buysse DJ, Sanders MH, Strollo P, Newman AB, Unruh ML. Sleep-disordered breathing and excessive daytime sleepiness in chronic kidney disease and hemodialysis. Clin J Am Soc Nephrol 2011;6:986-994.
5. Sakaguchi Y, Shoji T, Kawabata H, Niihata K, Suzuki A, Kaneko T, Okada N, Isaka Y, Rakugi H, Tsubakihara Y. High prevalence of obstructive sleep apnea and its association with renal function among nondialysis chronic kidney disease patients in Japan: a cross-sectional study. Clin J Am Soc Nephrol 2011;6:995-1000.
6. Ahmed SB, Ronksley PE, Hemmelgarn BR, Tsai WH, Manns BJ, Tonelli M, Klarenbach SW, Chin R, Clement FM, Hanly PJ. Nocturnal hypoxia and loss of kidney function. PLoS ONE 2011;6:e19029.
7. Sakaguchi Y, Hatta T, Hayashi T, Shoji T, Suzuki A, Tomida K, Okada N, Rakugi H, Isaka Y, Tsubakihara Y. Association of nocturnal hypoxemia with progression of CKD. Clin J Am Soc Nephrol 2013;8:1502-1507.
8. Epstein LJ, Kristo D, Strollo PJ Jr, Friedman N, Malhotra A, Patil SP, Ramar K, Rogers R, Schwab RJ, Weaver EM, et al.; Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009;5:263-276.
9. Hostetter TH. Prevention of the development and progression of renal disease. J Am Soc Nephrol 2003; 14(Suppl 2):S144-S147.
10. Friederich-Persson M, Thörn E, Hansell P, Nangaku M, Levin M, Palm F. Kidney hypoxia, attributable to increased oxygen consumption, induces nephropathy independently of hyperglycemia and oxidative stress. Hypertension 2013;62:914-919.
11. Fletcher EC, Bao G, Li R. Renin activity and blood pressure in response to chronic episodic hypoxia. Hypertension 1999;34:309-314.
12. Fletcher EC, Orolinova N, Bader M. Blood pressure response to chronic episodic hypoxia: the renin-angiotensin system. J Appl Physiol (1985) 2002;92:627-633.
13. Foster GE, Hanly PJ, Ahmed SB, Beaudin AE, Pialoux V, Poulin MJ. Intermittent hypoxia increases arterial blood pressure in humans through a Renin-Angiotensin system-dependent mechanism. Hypertension 2010;56:369-377.
14. Khan UA, Garg AX, Parikh CR, Coca SG. Prevention of chronic kidney disease and subsequent effect on mortality: a systematic review and meta-analysis. PLoS ONE 2013;8:e71784.
15. Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GF. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2012;12:CD004136.
16. Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens 2010;24:532-537.
17. Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM, Oparil S, Cofield SS, Calhoun DA. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med 2010;6:363-368.
18. Møller DS, Lind P, Strunge B, Pedersen EB. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens 2003;16:274-280.
19. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007;131:453-459.
20. Kraiczi H, Hedner J, Peker Y, Carlson J. Increased vasoconstrictor sensitivity in obstructive sleep apnea. J Appl Physiol (1985) 2000;89:493-498.
21. Svatikova A, Olson LJ, Wolk R, Phillips BG, Adachi T, Schwartz GL, Somers VK. Obstructive sleep apnea and aldosterone. Sleep 2009;32:1589-1592.
22. Kinebuchi S, Kazama JJ, Satoh M, Sakai K, Nakayama H, Yoshizawa H, Narita I, Suzuki E, Gejyo F. Short-term use of continuous positive airway pressure ameliorates glomerular hyperfiltration in patients with obstructive sleep apnoea syndrome. Clin Sci (Lond) 2004;107:317-322.
23. Hollenberg NK, Chenitz WR, Adams DF, Williams GH. Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man. J Clin Invest 1974;54:34-42.
24. Hollenberg NK, Williams GH, Taub KJ, Ishikawa I, Brown C, Adams DF. Renal vascular response to interruption of the renin-angiotensin system in normal man. Kidney Int 1977;12:285-293.
25. Shoback DM, Williams GH, Moore TJ, Dluhy RG, Podolsky S, Hollenberg NK. Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension. J Clin Invest 1983;72:2115-2124.
26. Nicholl DD, Hanly PJ, Handley GB, Hemmelgarn BR, Poulin MJ, Sola DY, Ahmed SB. Obstructive sleep apnea treatment improves renin angiotensin system activity in humans. J Am Soc Nephrol 2012;23:605A-606A.
27. Issa FG, Morrison D, Hadjuk E, Iyer A, Feroah T, Remmers JE. Digital monitoring of sleep-disordered breathing using snoring sound and arterial oxygen saturation. Am Rev Respir Dis 1993;148:1023-1029.
28. Vázquez JC, Tsai WH, Flemons WW, Masuda A, Brant R, Hajduk E, Whitelaw WA, Remmers JE. Automated analysis of digital oximetry in the diagnosis of obstructive sleep apnoea. Thorax 2000;55:302-307.
29. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D'Agostino RB, Newman AB, Lebowitz MD, Pickering TG. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000;283:1829-1836.
30. Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension 2010;55:1283-1288.
31. Miller JA, Anacta LA, Cattran DC. Impact of gender on the renal response to angiotensin II. Kidney Int 1999;55:278-285.
32. Kawasaki T, Itoh K, Uezono K, Sasaki H. A simple method for estimating 24 h urinary sodium and potassium excretion from second morning voiding urine specimen in adults. Clin Exp Pharmacol Physiol 1993;20:7-14.
33. Bauer JH, Sunderrajan S, Reams G. Effects of calcium entry blockers on renin-angiotensin-aldosterone system, renal function and hemodynamics, salt and water excretion and body fluid composition. Am J Cardiol 1985;56:62H-67H.
34. Bosma RJ, Kwakernaak AJ, van der Heide JJ, de Jong PE, Navis GJ. Body mass index and glomerular hyperfiltration in renal transplant recipients: cross-sectional analysis and long-term impact. Am J Transplant 2007;7:645-652.
35. du Cailar G, Ribstein J, Mimran A. Glomerular hyperfiltration and left ventricular mass in mild never-treated essential hypertension. J Hypertens Suppl 1991;9:S158-S159.
36. Fliser D, Franek E, Joest M, Block S, Mutschler E, Ritz E. Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int 1997;51:1196-1204.
37. Schmieder RE, Messerli FH, Garavaglia G, Nunez B. Glomerular hyperfiltration indicates early target organ damage in essential hypertension. JAMA 1990;264:2775-2780.
38. Kohler M, Stradling JR. Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol 2010;7:677-685.
39. Saarelainen S, Hasan J, Siitonen S, Seppälä E. Effect of nasal CPAP treatment on plasma volume, aldosterone and 24-h blood pressure in obstructive sleep apnoea. J Sleep Res 1996;5:181-185.
40. Follenius M, Krieger J, Krauth MO, Sforza F, Brandenberger G. Obstructive sleep apnea treatment: peripheral and central effects on plasma renin activity and aldosterone. Sleep 1991;14:211-217.
41. Meston N, Davies RJ, Mullins R, Jenkinson C, Wass JA, Stradling JR. Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea. J Intern Med 2003;254:447-454.
42. Cherney DZ, Scholey JW, Nasrallah R, Dekker MG, Slorach C, Bradley TJ, Hé bert RL, Sochett EB, Miller JA. Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 2008;294:F1336-F1341.
43. Ahmed SB, Kang AK, Burns KD, Kennedy CR, Lai V, Cattran DC, Scholey JW, Miller JA. Effects of oral contraceptive use on the renal and systemic vascular response to angiotensin II infusion. J Am Soc Nephrol 2004;15:780-786.
44. Splenser AE, Fisher ND, Danser AH, Hollenberg NK. Renal plasma flow: glomerular filtration rate relationships in man during direct renin inhibition with aliskiren. J Am Soc Hypertens 2009;3:315-320.
45. Pépin JL, Tamisier R, Barone-Rochette G, Launois SH, Lévy P, Baguet JP. Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 2010;182:954-960.
46. Engleman HM, Kingshott RN, Wraith PK, Mackay TW, Deary IJ, Douglas NJ. Randomized placebo-controlled crossover trial of continuous positive airway pressure for mild sleep Apnea/Hypopnea syndrome. Am J Respir Crit Care Med 1999;159:461-467.
47. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
48. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
49. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
50. Pimenta E, Calhoun DA, Oparil S. Sleep apnea, aldosterone, and resistant hypertension. Prog Cardiovasc Dis 2009;51:371-380.
51. Quan SF, Budhiraja R, Clarke DP, Goodwin JL, Gottlieb DJ, Nichols DA, Simon RD, Smith TW, Walsh JK, Kushida CA. Impact of treatment with continuous positive airway pressure (CPAP) on weight in obstructive sleep apnea. J Clin Sleep Med 2013;9:989-993.
52. Redenius R, Murphy C, O'Neill E, Al-Hamwi M, Zallek SN. Does CPAP lead to change in BMI? J Clin Sleep Med 2008;4:205-209.
53. Garcia JM, Sharafkhaneh H, Hirshkowitz M, Elkhatib R, Sharafkhaneh A. Weight and metabolic effects of CPAP in obstructive sleep apnea patients with obesity. Respir Res 2011;12:80.
54. Ahmed SB, Fisher ND, Stevanovic R, Hollenberg NK. Body mass index and angiotensin-dependent control of the renal circulation in healthy humans. Hypertension 2005;46:1316-1320.
55. de Leeuw PW, Meggs LG, Hollenberg NK. Renal vascular tachyphylaxis to angiotensin II: specificity of the response for angiotensin. Life Sci 1982;30:813-819.
56. Hollenberg NK, Meyerovitz M, Harrington DP, Sandor T. Influence of norepinephrine and angiotensin II on vasomotion of renal blood supply in humans. Am J Physiol 1987;252:H941-H944.
57. Williams GH, Cain JP, Dluhy RG, Underwood RH. Studies of the control of plasma aldosterone concentration in normal man. I. Response to posture, acute and chronic volume depletion, and sodium loading. J Clin Invest 1972;51:1731-1742.
58. Shoback DM, Williams GH, Swartz SL, Davies RO, Hollenberg NK. Time course and effect of sodium intake on vascular and hormonal responses to enalapril (MK 421) in normal subjects. J Cardiovasc Pharmacol 1983;5:1010-1018.
59. Chidambaram M, Duncan JA, Lai VS, Cattran DC, Floras JS, Scholey JW, Miller JA. Variation in the renin angiotensin system throughout the normal menstrual cycle. J Am Soc Nephrol 2002;13:446-452.
60. Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc 2008;5:173-178.
61. Weaver TE, Kribbs NB, Pack AI, Kline LR, Chugh DK, Maislin G, Smith PL, Schwartz AR, Schubert NM, Gillen KA, et al. Night-to-night variability in CPAP use over the first three months of treatment. Sleep 1997;20:278-283.
62. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007;59:251-287.
63. Price DA, Fisher ND, Osei SY, Lansang MC, Hollenberg NK. Renal perfusion and function in healthy African Americans. Kidney Int 2001;59:1037-1043.
64. Price DA, Fisher ND, Lansang MC, Stevanovic R, Williams GH, Hollenberg NK. Renal perfusion in blacks: alterations caused by insuppressibility of intrarenal renin with salt. Hypertension 2002;40:186-189.
65. Fisher ND, Price DA, Litchfield WR, Williams GH, Hollenberg NK. Renal response to captopril re flects state of local renin system in healthy humans. Kidney Int 1999;56:635-641.
66. Faccenda JF, Mackay TW, Boon NA, Douglas NJ. Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med 2001;163:344-348.
67. Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, Mullins R, Jenkinson C, Stradling JR, Davies RJ. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002;359:204-210.